| ID | 10150 |
| Vaccine Name | Covigenix VAX-001 |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | DNA based vaccine |
| Vaccine Status | Phase 1 |
| Manufacturer | Entos Pharmaceuticals Inc. |
| Year of Manufacturing | 2020 |
| Manufacturing Country | Canada |
| Age | 18 - 85 years |
| Dosage | 2 doses 14 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | Spike protein of SARS-CoV-2 virus |
| Description | Fusogenix PLV |
| Approving Organisation | NA |
| Collaborating Organisation | Canadian Institutes of Health Research |
| Other Countries | NA |
| Trade Name | NA |
| PMID | NA |
| Clinical Trial ID | NCT04591184 |
| Reference Link | https://clinicaltrials.gov/ct2/show/NCT04591184 |
| Additional Links | https://clinicaltrials.gov/ct2/history/NCT04591184
|